[1] SEEBACH E, KUBATZKY KF. Chronic Implant-Related Bone Infections-Can Immune Modulation be a Therapeutic Strategy? Front Immunol. 2019; 10:1724.
[2] WALSH MC, KIM N, KADONO Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33-63.
[3] ZHAO H, LU A, HE X. Roles of MicroRNAs in Bone Destruction of Rheumatoid Arthritis. Front Cell Dev Biol. 2020;8:600867.
[4] RAUT N, WICKS SM, LAWAL TO, et al. Epigenetic regulation of bone remodeling by natural compounds. Pharmacol Res. 2019;147:104350.
[5] DEL PUENTE A, ESPOSITO A, DEL PUENTE A, et al. Physiopathology of osteoporosis: from risk factors analysis to treatment. J Biol Regul Homeost Agents. 2015;29(3):527-531.
[6] PARK DR, KIM J, KIM GM, et al. Osteoclast-associated receptor blockade prevents articular cartilage destruction via chondrocyte apoptosis regulation. Nat Commun. 2020;11(1):4343.
[7] KIM JH, KIM N. Signaling Pathways in Osteoclast Differentiation. Chonnam Med J. 2016;52(1):12-17.
[8] KIM JH, KIM N. Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab. 2014;21(4):233-241.
[9] MARTIN TJ. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop. 2013;4(4):186-197.
[10] LIU J, ZHANG HX, LU XX, et al. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies. Genet Test Mol Biomarkers. 2014;18(2):117-122.
[11] D’AMICO D, ANDREUX PA, VALDÉS P, et al. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends Mol Med. 2021;27(7):687-699.
[12] SAHA P, YEOH BS, SINGH R, et al. Gut Microbiota Conversion of Dietary Ellagic Acid into Bioactive Phytoceutical Urolithin A Inhibits Heme Peroxidases. PLoS One. 2016;11(6):e0156811.
[13] NORDEN E, HEISS EH. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells. Carcinogenesis. 2019;40(1):93-101.
[14] LIN X, YUAN G, LI Z, et al. Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption. J Cell Physiol. 2020;35(9):5951-5961.
[15] RANTLHA M, SAGAR T, KRUGER MC, et al. Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway. Arch Pharm Res. 2017;40(1):79-87.
[16] XU H, CHEN F, LIU T, et al. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways. Chem Biol Interact. 2020;331:109235.
[17] LEE HJ, JUNG YH, CHOI GE, et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis. Cell Death Differ. 2021;28(1):184-202.
[18] KIM KB, LEE S, KIM JH. Neuroprotective effects of urolithin A on H(2)O(2)-induced oxidative stress-mediated apoptosis in SK-N-MC cells. Nutr Res Pract. 2020;14(1):3-11.
[19] DASILVA NA, NAHAR PP, MA H, et al. Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutr Neurosci. 2019;22(3):185-195.
[20] RIGGS BL, WAHNER HW, DUNN WL, et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981;67(2):328-335.
[21] RIGGS BL, WAHNER HW, SEEMAN E, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70(4):716-723.
[22] O’BRIEN MS, MCDOUGALL JJ. Age and frailty as risk factors for the development of osteoarthritis. Mech Ageing Dev. 2019;180:21-28.
[23] PEREIRA D, SEVERO M, RAMOS E, et al. Potential role of age, sex, body mass index and pain to identify patients with knee osteoarthritis. Int J Rheum Dis. 2017;20(2):190-198.
[24] MURATOVIC D, FINDLAY DM, CICUTTINI FM, et al. Bone matrix microdamage and vascular changes characterize bone marrow lesions in the subchondral bone of knee osteoarthritis. Bone. 2018;108:193-201.
[25] XU Q, CAO Z, XU J, et al. Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases. J Drug Target. 2022;30(4):394-412.
[26] HUANG WC, LIOU CJ, SHEN SC, et al. Urolithin A Inactivation of TLR3/TRIF Signaling to Block the NF-κB/STAT1 Axis Reduces Inflammation and Enhances Antioxidant Defense in Poly(I:C)-Induced RAW264.7 Cells. Int J Mol Sci. 2022;23(9):4697.
[27] KOMATSU W, KISHI H, YAGASAKI K, et al. Urolithin A attenuates pro-inflammatory mediator production by suppressing PI3-K/Akt/NF-κB and JNK/AP-1 signaling pathways in lipopolysaccharide-stimulated RAW264 macrophages: Possible involvement of NADPH oxidase-derived reactive oxygen species. Eur J Pharmacol. 2018;833:411-424.
[28] ZHANG W, CHEN JH, AGUILERA-BARRANTES I, et al. Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression. Mol Nutr Food Res. 2016;60(11):2387-2395.
[29] ALAUDDIN M, OKUMURA T, RAJAXAVIER J, et al. Gut Bacterial Metabolite Urolithin A Decreases Actin Polymerization and Migration in Cancer Cells. Mol Nutr Food Res. 2020;64(7):e1900390.
[30] HSU H, LACEY DL, DUNSTAN CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999; 96(7):3540-3545.
[31] HAYMAN AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008;41(3):218-223.
[32] VääNäNEN HK, ZHAO H, MULARI M, et al. The cell biology of osteoclast function. J Cell Sci. 2000;113(Pt 3):377-381.
[33] LIU Y, WANG Z, MA C, et al. Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity. J Cell Mol Med. 2020;24(6):3303-3313.
[34] TAKAYANAGI H, KIM S, KOGA T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889-901.
[35] LIU Y, WANG C, WANG G, et al. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics. 2019;9(16):4648-4662.
[36] LOTINUN S, KIVIRANTA R, MATSUBARA T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123(2):666-681.
[37] WU H, XU G, LI YP. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res. 2009;24(5):871-885.
[38] KIM Y, KIM J, LEE H, et al. Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage. Int J Mol Sci. 2019;20(16):4038.
[39] LEE K, SEO I, CHOI MH, et al. Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology. Int J Mol Sci. 2018;19(10):3004.
[40] WEI W, PENG C, GU R, et al. Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway. Eur J Pharmacol. 2022;921:174865. |